Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis

References

• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652.
   PubMed Web of Science ®Google Scholar
• Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–1927.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43(8):1018–1027.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–1168.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression- free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–59.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Puccini B, Zinzani PL, et al. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol. 2015;90(6):499–503.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–3752.
   PubMed Web of Science ®Google Scholar
• Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412–418.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928–937.
   PubMedGoogle Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–2511.
   PubMed Web of Science ®Google Scholar
• Deniz K, O’Mahony S, Ross G, et al. Breast cancer in women after treatment for Hodgkin’s disease. Lancet Oncol. 2003;4(4):207–214.
   PubMed Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94(3):182–192.
   PubMedGoogle Scholar
• Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721–1727.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III trial by the German Hodgkin study group. J Clin Oncol. 2019; 37(31):2835–2846.
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018;131(15):1666–1678.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman D, Tetzlaff C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(1):b2700–b2700.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff C, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Parmar MR, Torri V, Stewart L. Extracting summary statistic to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–2834.
   PubMed Web of Science ®Google Scholar
• Holscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol. 2006;78:123–130.
   PubMed Web of Science ®Google Scholar
• Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10(1):54.
   PubMedGoogle Scholar
• The Cochrane Collaboration. Cochrane handbook for systemic review of interventions. The Cochrane collaboration. Vol Version 5.
   Google Scholar
• Gac A, Chartier L, Girinsky T, et al. Outcome and treatment of relapsing early PET negative patients included in the EORTC/LYSA/FIL H10 trial on stages I/II Hodgkin lymphoma. Hematol Oncol. 2019;37:294–296.
   Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–4206.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–4246.
   PubMed Web of Science ®Google Scholar
• Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72(1):24–33.
   PubMed Web of Science ®Google Scholar
• Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long term risk of subsequent malignant neoplasms after treatment of childhood cancer in DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35(20):2288–2298.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33(6):625–633.
   PubMed Web of Science ®Google Scholar